Vanderbilt University has been selected as one of seven Dedicated Centers in the nation for the next phase of the Chemical Biology Consortium (CBC), a national network of scientists on the leading edge of cancer drug discovery.

New findings identify isoketal-modified proteins as a previously unrecognized feature of pulmonary fibrosis and as a potential therapeutic target for this disease.

A genetic risk factor for Alzheimer’s disease in later life appears to benefit younger adults as they age.

In a twist on the usual research narrative, Justin Siemann, Ph.D., who celebrated his doctoral degree in Neuroscience at last week’s Graduate School Commencement, conducted research on patients first, and then moved to the laboratory bench.

The primary method used to test compounds for anti-cancer activity in cells is flawed, Vanderbilt University researchers reported May 2 in Nature Methods.

Vanderbilt researchers have discovered that activation of a certain signaling pathway protects brain cancers from targeted therapies, suggesting that using therapeutics that block both pathways may be a promising treatment.